RecruitingNCT06827262
Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
Sponsor
Boston Scientific Corporation
Enrollment
1,500 participants
Start Date
Mar 26, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Study candidate is scheduled to be treated with a commercially approved Intracept™ Intraosseous Nerve Ablation System per local Instructions for Use (IFU).
- Signed a valid, IRB/EC-approved informed consent form.
Exclusion Criteria1
- Meets any contraindications per locally applicable Instructions for Use (IFU).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEIntracept™ Intraosseous Nerve Ablation
Intracept™ Intraosseous Nerve Ablation for treatment of patients diagnosed with vertebrogenic pain
Locations(17)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06827262
Related Trials
The Ability of Chronic Pain Patients to Self-diagnose Their Chief Source of Low Back Pain
NCT066306761 location
Detection of EEG-Based Biomarkers of Chronic Low Back Pain
NCT060252011 location
Managing Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control
NCT071908077 locations
Effectiveness of Thoracolumbar Fascia Mobilization and Ultrasound-Guided 5% Dextrose Injection in Chronic Low Back Pain
NCT072415591 location
Telerehabilitation for Patients With Chronic Low Back Pain (TeleBACK Clinical Trial)
NCT068216073 locations